
New UK & Ireland general manager for Teva
pharmafile | October 10, 2016 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Teva, appointment
Kim Innes has been appointed by Teva as its new general manager of UK & Ireland. Innes succeeds Richard Daniell, bringing to the role nearly 25 years of experience in the industry.
She headed up Teva’s UK generics business unit in 2006, climbing to the position of chief operating officer where she was a crucial cornerstone in negotiating the firm’s acquisition of Allergan’s generics branch, the newly-sold Actavis Generics. She also served as chair of the British Generic Manufacturer’s Association for two years.
“I am excited to be leading this great organisation at what is a transformational time for both Teva as a company and the pharmaceutical industry as a whole,” Innes said of her promotion. “We have an extremely talented group of people here in the UK and Ireland and I am confident that we will continue to maintain our leadership position while keeping an absolute focus on our patients and customers.”
Related Content

Teva’s Ajovy significantly reduces migraine in children and adolescents
Teva’s Ajovy (fremanezumab) has demonstrated significant reduction in monthly migraine and headache days in children …

Teva announces positive results from trial of AJOVY for migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.






